Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tumor neoantigens: from basic research to clinical applications
Tao Jiang, Tao Shi, Henghui Zhang, et al.
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 325

Showing 1-25 of 325 citing articles:

Immune checkpoint therapy—current perspectives and future directions
Padmanee Sharma, Sangeeta Goswami, Deblina Raychaudhuri, et al.
Cell (2023) Vol. 186, Iss. 8, pp. 1652-1669
Closed Access | Times Cited: 441
Neoantigens: promising targets for cancer therapy
Na Xie, Guobo Shen, Wei Gao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 439
RNA sequencing: new technologies and applications in cancer research
Mingye Hong, Shuang Tao, Ling Zhang, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 411
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
Rilan Bai, Zheng Lv, Dongsheng Xu, et al.
Biomarker Research (2020) Vol. 8, Iss. 1
Open Access | Times Cited: 384
The Intriguing History of Cancer Immunotherapy
Paula Dobosz, Tomasz Dzieciątkowski
Frontiers in Immunology (2019) Vol. 10
Open Access | Times Cited: 357
Turning cold tumors hot: from molecular mechanisms to clinical applications
Jiahui Zhang, Di Huang, Phei Er Saw, et al.
Trends in Immunology (2022) Vol. 43, Iss. 7, pp. 523-545
Closed Access | Times Cited: 312
Proteogenomics of Non-smoking Lung Cancer in East Asia Delineates Molecular Signatures of Pathogenesis and Progression
Yi‐Ju Chen, Theodoros I. Roumeliotis, Ya-Hsuan Chang, et al.
Cell (2020) Vol. 182, Iss. 1, pp. 226-244.e17
Open Access | Times Cited: 267
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
Yuchen Wang, Hao Zhang, Chao Liu, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 169
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
Carlo Genova, Chiara Dellepiane, Paolo Carrega, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 160
New Insights Into the Cancer–Microbiome–Immune Axis: Decrypting a Decade of Discoveries
Tejeshwar Jain, Prateek Sharma, Abhi C. Are, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 130
T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors
Apostolia M. Tsimberidou, Karlyle Van Morris, Henry Hiep Vo, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 117
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Meng Qiao, Tao Jiang, Xinyu Liu, et al.
Journal of Thoracic Oncology (2021) Vol. 16, Iss. 8, pp. 1267-1288
Closed Access | Times Cited: 114
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
Di Huang, Xiao‐Feng Zhu, Shuying Ye, et al.
Nature (2023) Vol. 625, Iss. 7995, pp. 593-602
Closed Access | Times Cited: 81
The theory of tumor ecosystem
Xueman Chen, Erwei Song
Cancer Communications (2022) Vol. 42, Iss. 7, pp. 587-608
Open Access | Times Cited: 78
Challenges in neoantigen-directed therapeutics
Lien Lybaert, Steve Lefever, Bruno Fant, et al.
Cancer Cell (2022) Vol. 41, Iss. 1, pp. 15-40
Open Access | Times Cited: 72
Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
Zhifei Gao, Yifeng Bai, Anqi Lin, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 65
Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell
Lu Diao, Mi Liu
Advanced Science (2023) Vol. 10, Iss. 22
Open Access | Times Cited: 63
Immunologic tumor microenvironment modulators for turning cold tumors hot
Gholamreza Khosravi, Samaneh Mostafavi, Sanaz Bastan, et al.
Cancer Communications (2024) Vol. 44, Iss. 5, pp. 521-553
Open Access | Times Cited: 51
Tumor heterogeneity: preclinical models, emerging technologies, and future applications
Marco Proietto, Martina Crippa, C. Damiani, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 49
Designing neoantigen cancer vaccines, trials, and outcomes
Nupur Biswas, Shweta Chakrabarti, Vijay Padul, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 43
Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 35
mRNA delivery systems for cancer immunotherapy: Lipid nanoparticles and beyond
Mariona Estapé Sentí, Lucía García del Valle, Raymond M. Schiffelers
Advanced Drug Delivery Reviews (2024) Vol. 206, pp. 115190-115190
Open Access | Times Cited: 21
Clinical advances of mRNA vaccines for cancer immunotherapy
Alexey V. Yaremenko, Muhammad Muzamil Khan, Xueyan Zhen, et al.
Med (2025) Vol. 6, Iss. 1, pp. 100562-100562
Closed Access | Times Cited: 4
Competitive glucose metabolism as a target to boost bladder cancer immunotherapy
Julieta Afonso, Lúcio Lara Santos, Adhemar Longatto‐Filho, et al.
Nature Reviews Urology (2020) Vol. 17, Iss. 2, pp. 77-106
Closed Access | Times Cited: 113
Selecting Target Antigens for Cancer Vaccine Development
Luigi Buonaguro, Maria Tagliamonte
Vaccines (2020) Vol. 8, Iss. 4, pp. 615-615
Open Access | Times Cited: 104
Page 1 - Next Page

Scroll to top